Related Experiment Videos
Angiotensin III is a new chemoattractant for polymorphonuclear leukocytes
Y Yamamoto1, T Yamamguchi, M Shimamura
1Department of Cancer Therapeutics, Tokyo Metropolitan Institute of Medical Science, Japan.
Biochemical and Biophysical Research Communications
|June 30, 1993
Summary
Angiotensin III (ANGIII) acts as a novel chemoattractant for human polymorphonuclear neutrophils (PMNs), influencing inflammation. Its signaling pathway may overlap with, yet differ from, that of N-formyl-Met-Leu-Phe (FMLP).
Area of Science:
- Immunology
- Biochemistry
- Cellular Biology
Background:
- Inflammation involves the migration of immune cells, such as polymorphonuclear neutrophils (PMNs).
- Angiotensin peptides play roles in various physiological processes, but their specific function in neutrophil chemotaxis is less understood.
Purpose of the Study:
- To investigate the role of angiotensin III (ANGIII) as a chemoattractant for human PMNs.
- To elucidate the potential signaling pathways involved in ANGIII-induced PMN chemotaxis.
Main Methods:
- Dose-response and time-course experiments were conducted to assess ANGIII-induced PMN chemotaxis.
- Comparative analysis with N-formyl-Met-Leu-Phe (FMLP), a known chemoattractant, was performed.
- Combined stimulation with ANGIII and FMLP was used to explore potential pathway interactions.
Main Results:
- ANGIII demonstrated a dose-dependent effect on PMN chemotaxis, with an optimal concentration of 10(-10) M.
- Maximal chemotaxis elicited by ANGIII occurred at 90 minutes, compared to 60 minutes for FMLP.
- Combined ANGIII and FMLP stimulation did not yield significantly higher chemotaxis than individual peptides, suggesting shared signaling components.
Conclusions:
- ANGIII is identified as a novel chemoattractant for human PMNs.
- The findings suggest that ANGIII may utilize a signal transduction pathway similar to, but distinct from, that of FMLP.
- This discovery opens new avenues for understanding inflammatory processes and potential therapeutic targets.